Skip to content

Lantern Pharma Inc.

LTRN

CIK 0001763950

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$16.37M
+17.6% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.51
+18.7% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$14.98M
Q1 May 2026
Cash
$4.92M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
11.3M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings